Cumberland Pharmaceuticals
CPIX
48 hedge funds and large institutions have $30.1M invested in Cumberland Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
4% more funds holding
Funds holding: 46 → 48 (+2)
19% less capital invested
Capital invested by funds: $37.2M → $30.1M (-$7.13M)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$520K |
| 2 |
EGA
Eagle Global Advisors
Houston,
Texas
|
+$98.1K |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$68.2K |
| 4 |
Renaissance Technologies
New York
|
+$11.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$11.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$267K |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
-$131K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$102K |
| 4 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$89.4K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$16.9K |
CPIX Hedge Fund Activity: Q3 2015 in Review
48 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q3 2015, worth a combined $30.1M — down 19% from $37.2M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CPIX positions and 1 closed out — a net gain of 2 holders — while 10 added to existing stakes and 15 trimmed.
The largest buyer was Stanley-Laman Group, opening a new position worth an estimated $520K. The largest seller was GSA Capital Partners, cutting an estimated $267K.
- 48 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q3 2015, up from 46 in Q2 2015.
- Funds reported $30.1M of Cumberland Pharmaceuticals stock for Q3 2015, down 19% quarter-over-quarter.
- 3 funds opened new Cumberland Pharmaceuticals positions in Q3 2015 and 1 closed out, a net change of +2 holders.
- The largest Cumberland Pharmaceuticals buyer in Q3 2015 was Stanley-Laman Group, an estimated $520K added.
- The largest Cumberland Pharmaceuticals seller in Q3 2015 was GSA Capital Partners, an estimated $267K sold.
Based on aggregated 13F filings for Q3 2015.